Intravitreal Bevacizumab for Diabetic Macular Edema

NCT00703235 | Unknown Phase 2

• 1 other identifier: MUI - clinical - 185290
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

Diabetic macular edema is a common cause of visual loss among diabetic patients. Studies have demonstrated the role of vascular endothelial growth factor (VEGF) in the pathogenesis of edema. This study designed to evaluate the effect of Intravitreal injection of a recombinant monoclonal anti-VEGF antibody, Bevacizumab, for treatment of diabetic macular edema.

Conditions

Macular Edema; Diabetic Retinopathy

Interventions

Bevacizumab DRUG

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Diabetes mellitus
• Clinically significant macular edema
• Possibility of performing macular OCT

You may not qualify if:

• Necessity of surgical intervention
• Rejection of the remaining in the study by patient

Sponsors & Collaborators

• Isfahan Ophthalmology Research Center: lead

MeSH Terms

Conditions

Macular Edema; Diabetic Retinopathy

Interventions

Bevacizumab

Condition Hierarchy (Ancestors)

Macular Degeneration; Retinal Degeneration; Retinal Diseases; Eye Diseases; Diabetic Angiopathies; Vascular Diseases; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Endocrine System Diseases

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins

Study Design

• Study Type: interventional
• Phase: phase 2
• Sponsor Type: NETWORK

Study Record Dates

• First Submitted: June 20, 2008
• First Posted: June 23, 2008
• Last Updated: June 23, 2008

Record last verified: 2008-06